New antiplatelet therapies for acute coronary syndromes

被引：2
|
作者：
Rich J.D. [1 ]
Wiviott S.D. [1 ]
机构：
[1] Cardiovascular Division, Brigham and Women's Hospital, TIMI Study Group, Boston
来源：
Current Cardiology Reports | 2007年 / 9卷 / 4期
关键词：
Percutaneous Coronary Intervention; Acute Coronary Syndrome; Clopidogrel; Abciximab; P2Y12 Receptor;
D O I：
10.1007/BF02938379
中图分类号：
学科分类号：
摘要：
Platelets play a central role in the pathophysiology of acute coronary syndromes (ACS). Dual antiplatelet therapy has resulted in significant advances in the treatment of ACS; however, ACS remains an important cause of morbidity and mortality. Important limitations exist among the current antiplatelet agents and therefore a pressing need for the development of improved antiplatelet agents exists. Three antiplatelet agents currently under investigation (prasugrel, AZD6140, and cangrelor) in clinical trials for the treatment of ACS appear promising. Copyright © 2007 by Current Medicine Group LLC.
引用
收藏
页码：303 / 311
页数：8
相关论文
共 50 条
  • [41] Smoking and antiplatelet therapy after acute coronary syndromes
    Flather, Marcus
    Ayton, Sarah
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2020, 6 (06) : 382 - 383
  • [42] Use of Novel Antiplatelet Agents in Acute Coronary Syndromes
    Luna, Michael
    Holper, Elizabeth M.
    CURRENT ATHEROSCLEROSIS REPORTS, 2015, 17 (03)
  • [43] Antiplatelet strategies in ageing patients with acute coronary syndromes
    Sinnaeve, Peter R.
    Gevaert, Sofie A.
    LANCET, 2020, 395 (10233): : 1319 - 1321
  • [44] Adjunctive therapies in the treatment of acute coronary syndromes
    Miller, WL
    Reeder, GS
    MAYO CLINIC PROCEEDINGS, 2001, 76 (04) : 391 - 405
  • [45] Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: Insights from the Global Registry of Acute Coronary Events (GRACE)
    Budaj, A
    Brieger, D
    Steg, PG
    Goodman, SG
    Dabbous, OH
    Fox, KAA
    Avezum, A
    Cannon, CP
    Mazurek, T
    Flather, MD
    Van De Werf, F
    AMERICAN HEART JOURNAL, 2003, 146 (06) : 999 - 1006
  • [46] Use of the New Antiplatelet Agents in Acute Coronary Syndromes: Limitations Related to Patient Characteristics
    Castillo, Francisco J.
    Anguita, Manuel
    Castillo, Juan C.
    Ruiz, Martin
    Mesa, Dolores
    Suarez de Lezo, Jose
    REVISTA ESPANOLA DE CARDIOLOGIA, 2015, 68 (05): : 448 - 450
  • [47] Safety of New Oral Anticoagulants with Dual Antiplatelet Therapy in Patients with Acute Coronary Syndromes
    Tsu, Laura V.
    Dager, William E.
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (04) : 573 - 577
  • [48] Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor
    De Servi, Stefano
    Navarese, Eliano Pio
    D'Urbano, Maurizio
    Savonitto, Stefano
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (11) : 2117 - 2122
  • [49] Prominent features of management strategies in acute coronary syndromes with the new oral antiplatelet agents
    Enar, Rasim
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2013, 41 (02): : 166 - 171
  • [50] Clinical use of new antithrombotic therapies for medical management of acute coronary syndromes
    Wiggins, BS
    Wittkowsky, AK
    Nappi, JM
    PHARMACOTHERAPY, 2001, 21 (03): : 320 - 337
12345